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Abstract
Nasopharyngeal carcinoma (NPC) is an EBV-associated malignant tumor of nasopharynx. As extremely rare
condition, the second primary cancer of nasopharynx can occur in NPC patients synchronously or subsequently.
Extramedullary plasmacytoma (EMP) is a rare tumor and commonly originates in the head and neck region.
However, there is no report to describe a collision tumor of NPC and EMP occurring in the same nasopharyngeal
mass. We report here an unusual case of synchronous coexistence of NPC and EMP occurring in the nasopharynx
of an old male patient. A 63-year-old male patient presented with a 3-month history of right-sided nasal
obstruction and recently intermittent epistaxis without enlargement of cervical lymph nodes. The solitary mass of
nasopharynx was found by radiological and nasopharyngeal examination. Histologically, the mass contained two
separated portions and displayed typically histological features of NPC and EMP, respectively. In EMP portion, the
tumor was composed of monomorphic plasmacytoid-appearing cells with immuno-positive to CD79a, CD138,
CD38, MUM-1 and CD56, but lack immunoreactivity to pan-CK (AE1/AE3), CD20, CD21 and EBERs. In NPC portion,
the tumor cells formed irregular-shaped islands with diffusely immuno-positive to pan-CK (AE1/AE3), EMA and
EBERs, but lack expressions of lymphoplasmacytic markers. A diagnosis of simultaneous occurrence of EMP and NPC
in nasopharynx was made. There was no evidence of tumor recurrence or metastasis 18-month follow-up after
radiotherapy. To our knowledge, it may be the first case of coexistence of EMP and NPC synchronously. In addition,
the histological differential diagnosis and relevant potential mechanism of this unusual collision tumor were also
discussed.
Background
Extramedullary (extraosseous) plasmacytoma (EMP) is
localized plasma cell neoplasm that arises in tissues other
than bone. It constitutes 3–5 % of all plasma cell neo-
plasm [1], and approximately 80 % of EMPs occur in the
upper respiratory tract, including the oropharynx, naso-
pharynx, sinuses and larynx [2, 3], although they have also
been described in other rare sites, such as gastrointestinal
tract [4], bladder [5], central nervous system [6] and thy-
roid [7]. EMPs in head and neck are seldom positive for
Epstein-Barr virus (EBV) [8], although they usually involve
the submucosal lymphoid tissue of the nasopharynx or
paranasal sinuses, a region rich in EBV-associated tumors.
However, nasopharyngeal carcinoma (NPC) is an EBV-
associated malignant tumor that has a high incidence
in southern China and Southeast Asia [9]. As exceed-
ingly rare condition, a collision tumor of NPC and
EBV-associated lymphoma, such as Hodgkin lymph-
oma, has been described in the literatures [10, 11].
However, so far there is no report to describe a coex-
istence of NPC and an EBV-negative EMP in naso-
pharynx simultaneously in the worldwide. Herein we
describe a case of synchronous occurrence of NPC
and EMP in nasopharynx at diagnosis. To our best
knowledge, it may be the first description of such an
event occurring.
Case presentation
Clinical manifestation and management
A 63-year-old Chinese male patient admitted to our hos-
pital with the complaints of a 3-month history of right-
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sided nasal obstruction and recently intermittent epi-
staxis. He had no remarkable medical or family history
and physical examination was normal. There were no
risk factors of NPC, such as consumption of salt-
preserved fish, tobacco smoking, and familiar susceptibil-
ity of NPC verified. The neck exam was benign without
appreciable lymphadenopathy. Nasopharyngeal examin-
ation revealed a smooth mass extending inferiorly from
the right fossa of Rossenmuller and effacing the posterior
pharyngeal wall. Routine laboratory test results, including
blood count, differential, liver and renal function, were
within the normal range. Serum and urine assays for M
protein and Bence-Jones protein were normal, and there
was no evidence of gammopathy. The serologic assess-
ment for titers of immunoglobulin A against EB viral cap-
sid antigen (VCA-IgA) and early antigen (EA-IgA) were
positive. Magnetic resonance imaging (MRI) of the naso-
pharynx showed the mass protruding from nasopharynx
(Fig. 1). An endoscopic examination and excisional biopsy
was performed. The final histological diagnosis was syn-
chronous occurrence of NPC and EMP in nasopharynx.
After diagnosis, the patient underwent radical radio-
therapy with a 45Gy dose in 20 fractions of the nasopha-
ryngeal field, which remarkably reduced the tumor size
and relieved nasal obstruction. However, his intermit-
tent epistaxis did not improve. After the radiation
therapy, the patient was referred to a whole body
F18-fluorodeoxyglucose (FDG) positron emission tom-
ography (PET)/CT study to search for the potentially
secondary tumor. But there were no detectable osteo-
lytic lesions and metastatic lesions. Bone marrow bi-
opsy was also performed for excluding multiple
myeloma, but the result was normal (Data not
shown). The second endoscopic examination and exci-
sional biopsy was performed. Histological examination re-
vealed that only EMP could be observed in the
nasopharyngeal tissues. He then received additional
radiation therapy (60Gy/30 fractions). The patient was
then followed up 18 months after the completion of treat-
ment. Physical examination, MRI of the nasopharynx and
neck, and a bone marrow aspiration were performed.
There was no evidence of relapse or metastasis.
Pathological findings
Both excisional biopsies were routinely fixed in 10 %
neutral buffered formalin. The tissues were embedded in
paraffin. Four micrometer-thick sections were stained
with H&E. Immunohistochemical analyses were per-
formed using the ChemMate Envision/HRP Kit (Dako,
Glostrup, Denmark). The antibodies used in this study
included a broad panel of antibodies against pan-
cytokeratin (AE1/AE3), epithelial membrane antigen
(EMA), CD20, CD21, CD79α, CD3, CD5, CD138, CD38,
MUM-1, CD56, kappa and lambda light chain. The anti-
bodies were obtained from Dako Cytomation (Glostrup,
Denmark) and Santa Cruz Biotechnology (Santa Cruz,
CA, USA). In situ hybridization for EBERs (EBV-
encoded RNAs) was performed on the biopsies by
EBERs detection kit (Glostrup, Denmark).
Microscopically, the first biopsy showed a diffuse infil-
tration of monomorphic round-to-oval cells with eccentric
nuclei in the subepithelial tissue. These round cells were
plasmacytoid-appearing with coarsely clumped chromatin
and amphophilic cytoplasm. Mitotic figures were present.
However, several irregular islands were also found in the
subepithelial tissue. The cell islands were composed of
syncytial-appearing large cells with indistinct cell borders,
round to oval vesicular nuclei and large central nucleoli.
These cells appeared to be crowded and overlapped, and
active mitotic figures were present (Fig. 2). Immunohisto-
chemically, the syncytial cell islands were strongly
positive to cytokeratin (AE1/AE3) and EMA, but
negative to lymphoplasmacytic markers. However, the
plasmacytoid cells were positive to CD79a, CD138,
Fig. 1 Radiological and nasopharyngeal endoscopic examination. a. MRI revealed a mass protruded from the mucosa of nasopharynx (white
arrow). b. Nasopharyngeal endoscopic examination revealed that a smooth well-circumscribed mass extended from the right fossa
of Rossenmuller
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CD38, MUM-1 and CD56. The presence of kappa light
chain restriction was also detected in plasmacytoid cells.
But they were negative to CD20, CD21, CD3, and CD5.
EBV detection by in situ hybridization for EBERs showed
the nuclear positive only in syncytial cell islands, and
the plasmacytoid cells were EBV-negative. In the sec-
ond nasopharyngeal biopsy, subepithelial tissue was
infiltrated by sheets of a monotonous population con-
sisting of medium-sized atypical plasmacytoid cells
without syncytial cell islands. Immunohistochemically,
the tumor cells were strongly positive for CD79a,
CD138, CD38 and MUM-1, as well as the presence of
kappa light chain restriction. EBV detection was non-
reactive (Fig. 3).
Fig. 2 Histological and immunohistological features of the first nasopharyngeal biopsy. a. There were several irregular-shaped cell islands found
in some areas of tissue. The cells were syncytial appearance with indistinct cell borders, oval vesicular nuclei and large central nucleoli. b In other
areas, diffuse infiltration of monomorphic plasmacytoid-appearing cells was observed in the subepithelial tissue. c. Immunohistochemically,
syncytial cell islands were diffusely positive to pan-CK (AE1/AE3). d. In situ hybridization assay showed that the syncytial cell islands were
EBERs-positive. e. However, the monomorphic plasmacytoid cells were diffusely immunoreactive to CD138, but lack the expression of
CD20 f. g. The presence of kappa light chain restriction was also detected in plasmacytoid cells. h. In situ hybridization assay revealed
that plasmacytoid cells were EBERs-negative. a-b, HE staining with original magnification × 400; c, e-g, immunohistochemical staining with
original magnification × 400; d, h, in situ hybridization for EBERs with original magnification × 400)
Du et al. Diagnostic Pathology  (2015) 10:170 Page 3 of 7
On the basis of histopathological features and immu-
nohistochemical phenotypes, its extramedullary location,
the presence of EBV-positive syncytial cell islands and
light chain restriction in plasmacytoid cells, a diagnosis
of synchronous occurrence of NPC and EMP in naso-
pharynx was made.
Discussion
Extramedullary plasmacytomas (EMPs) are rare tu-
mors, which represent 3 % of plasma cell neoplasms
and commonly originate in the head and neck region
[1]. Plasma cell neoplasm has been classified into
three subtypes. The most common type is multiple
myeloma, which is usually a disseminated disease and
is characterized by abnormal M protein. The other two
types, solitary plasmacytoma of the bone and EMP of the
soft tissue, are considerably less common. Approximately
80 % EMPs occur in head and neck region, and 40 %
occur in the nasal cavity and paranasal sinus, 20 % in the
nasopharynx, and 18 % in the oropharynx [12]. There is a
greater male preponderance (male: female ratio, 3:1) and
they occur during the fifth and seventh decades of life
[13]. The diagnostic criteria of EMP of the soft tissue have
been identified: (a) pathological tissue evidence of mono-
clonal plasma cells involving a single extramedullary site;
(b) no bone marrow involvement; (c) negative skeletal sur-
vey results; (d) no anemia, hypercalcemia or renal impair-
ment caused by plasma cell dyscrasia; (e) low serum or
urinary levels of monoclonal immunoglobulin [14]. More-
over, EMP can be staged according to the spread of the
disease. Stage I is disease confined to one site. Stage II in-
cludes tumors with local extension of lymph node involve-
ment. Stage III has metastatic spread. In the present case,
the tumor is localized in the nasopharynx and observed to
have monoclonal plasma cells proliferation with mildly
cellular atypia.
Due to its rarity, the diagnosis of EMP should be made
cautiously in clinical practice. The diagnosis is based on
Fig. 3 Histological and immunohistological features of the second nasopharyngeal biopsy. a. Subepithelial tissue was infiltrated by sheets of a
monotonous population consisting of medium-sized atypical plasmacytoid cells without syncytial cell islands. b. immunohistochemical staining
showed that the plasmacytoid cells were diffusely positive to CD138 and kappa light chain c, but they were negative to pan-CK (AE1/AE3) (the
neighboring epithelium was positive to pan-CK) d, CD20 e and not reactive to EBERs detection f. a, HE staining with original magnification × 400;
b-e, immunohistochemical staining with original magnification × 400; f, in situ hybridization for EBERs with original magnification × 400)
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a combination of pathological, radiological and clinical
features, because this tumor may sometimes be the first
manifestation of a systemic disease, multiple myeloma
(MM). The reported conversion rate of EMP to MM is
15–20 %, and is associated with a poorer prognosis [1].
However, generalized bone marrow involvement is typic-
ally present in MM. Radiological examination reveals os-
seous lytic lesions, osteoporosis or fractures, which is
often associated with bone pain and hypercalcemia. M-
protein is found in serum or urine in about 97 % of pa-
tients [15]. These radiological and clinical features can
not be observed in EMP. Solitary plasmacytomas of the
bone (SPB) should also be distinguished from EMP. Un-
like EMPs usually presenting as submucosal masses in
soft tissues, SPB is a localized bone tumor, and complete
skeletal radiographs show no other lesions. There are no
clinical features of MM and no evidence of bone marrow
plasmacytosis except for the solitary lesion [14, 16]. In our
case, there were no clinical features of MM found in pa-
tient, PET/CT and bone marrow biopsy showed no abnor-
malities. There was no evidence of infiltration to the bone
marrow or multiple bone destruction at the diagnosis.
The clinical features and histopathological findings of our
case are consistent with well-differentiated EMP of naso-
pharynx, Stage I.
For the present case, another important differential
diagnostic consideration that needs to be excluded is
extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue (MALT lymphoma) in naso-
pharynx. On the one hand, MALT lymphoma represents
one of the commonest hematolymphoid malignancies
arising in the salivary glands and head and neck. On the
other hand, plasmacytic differentiation is frequently found
in MALT, and histological and immunohistochemical fea-
tures of plasmacytic differentiation in MALT are similar to
those of plasmacytoma [17]. The diagnosis of EMP must
strictly exclude the MALT lymphoma with prominent
plasmacytic differentiation [18]. Based on the criteria de-
fined by WHO classification of tumors of haematopoietic
and lymphoid tissues, MALT lymphoma is a lymphoma
composed predominantly of small cells with CD20-
positive, CD79a-positive and expression of marginal zone
cell-associated antigens CD21 and CD35 [17]. In the
present case, the complete absence of CD20 and CD21 ex-
pression argues against a diagnosis of MALT. In addition,
EMP-like post-transplant lymphoproliferative disease
(PTLD) has previously been described, and this entity is
often associated with EBV [19]. However, the lack of a his-
tory of transplant or immunodeficiency and absence of
EBV infection in EMP tumor cells rule out this rare
disease.
Nasopharyngeal carcinoma (NPC) presents as an epi-
thelial cancer with histology that ranges from keratiniz-
ing and non-keratinizing forms. This tumor is endemic
in Southern China and Southeast Asia [9]. The undiffer-
entiated variant of NPC is universally associated with
EBV. Positive serology against EBV is found in close to
100 % of patients with non-keratinizing NPC, and VCA-
IgA and EA-IgA/IgG are the most extensively used diag-
nostic tool, with positive for NPC varying from 69–93 %
[20]. The underlying pathogenesis for EBV-related can-
cers has not been completely defined, but appears to be
mediated through activation of various cell signaling
pathways by EBV nuclear antigens (EBNAs) and latent
membrane proteins (LMPs). Some studies indicated that
different types of latent EBV expression profiles were as-
sociated with different malignancies. For example, a type
I latency pattern is typical of Burkitt’s lymphoma, and
type II is seen in NPC and Hodgkin lymphoma, as well
as PTLD [21]. Several cases of NPC and Hodgkin
lymphoma occurring in the same patients synchronously
or sequentially have been documented in the literature
[10, 11]. In those cases, dual EBV infection and different
oncogenic pathways activated by the same type of EBV
latency profile were suggested for coexistence of NPC
and Hodgkin lymphoma [22]. However, the same hy-
pothesis seems not suitable for the current case, because
EMP in our case is EBV-negative, although EBV-
associated EMPs occurring in head and neck have been
described in literature [23]. To the best of our know-
ledge, our case may be the first case of the simultaneous
occurrence of these two tumors.
Recent studies have focused on second primary cancers
in NPC patients and indicated that immune suppression,
shared genetic factors, and shared environmental risk fac-
tors might be the most important reasons to explain the
coexistence of NPC and other cancers in nasopharynx
[24]. Since cellular immunity is suppressed in patients
with NPC and the suppressed condition still remains
after remission [25], immune suppression might ex-
plain the increased incidence of cancers, especially
non-Hodgkin lymphoma, after NPC. There are some
common genetic susceptibility involved in NPC and
other cancers. For example, polymorphisms in two
DNA repair genes, XRCC1 and HOGG1, have been re-
ported to increase the risk of both lung cancer and
NPC [26]. Abnormal expression of XRCC1 or HOGG1
was also found in myeloid leukemia and the majority of
follicular lymphomas. These genetic abnormalities
might explain the coexistence of NPC and lung cancer,
myeloid leukemia, as well as follicular lymphoma.
However, so far there is no certain shared genetic alter-
ation found both in NPC and EMP. One study has pre-
viously reported the presence of RAS mutations only in
extramedullary plasma cells and not in intramedullary
plasma cells, suggesting a role for RAS mutations in
the development of EMP [27]. It is well known that
RAS gene abnormalities are closely associated with the
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development and progression of NPC. We wonder if
there are some potential links between RAS mutation
and synchronous occurrence of NPC and EMP. The
further studies should focus on those abnormal genetic
changes, which share in NPC and EMP and promote
the development and progression of NPC and EMP
simultaneously.
Environmental risk factor is another important factor
for tumor development. It has demonstrated that diet
habits, particularly Chinese-style salted fish, are common
environmental risk factors for tongue cancer, brain
tumor and NPC [28]. The environmental factors in-
volved in the simultaneous development of EMP and
NPC remain unclear. Since NPC has mainly been treated
with radiotherapy, radiation is likely to be an important
factor for malignancies occurrence after NPC treatment.
However, in the present case, the coexistence of NPC
and EMP did not support this hypothesis. We postulate
that the EMP in nasopharynx may have evolved as a re-
sult of a progression from a polyclonal inflammatory
population concomitant to the NPC. Immune suppres-
sion and chronic inflammatory stimulation might pro-
mote a clonal evolution of plasma cell, leading to a
plasmacytoma and collision tumor with NPC. However,
this postulation will be required to ascertain in the fur-
ther studies.
Plasmacytomas are generally associated with a more
favorable prognosis compared to MM. In most cases the
lesions are eradicated with local radiation therapy. About
70 % of patients remain disease free at 10 years [18].
Our presenting case also showed a favorable prognosis
after radiotherapy, and there was no evidence of relapse
or metastasis. This indolent course may suggest that
many cases of EMP are more closely related to MALT
lymphoma than to myeloma. However, subsequent
follow-up information of our patient will be required to
evaluate the biological behavior of collision tumor of
EMP and NPC.
Conclusion
In conclusion, our presenting case may be the first docu-
mented case of coexistence of NPC and EMP in nasophar-
ynx synchronously. Although the precise mechanism
involved in synchronous occurrence of two malignancies
remains unknown, it should be reflected that there may
be a relationship between NPC and EMP. Immune sup-
pression and chronic inflammatory stimulation might play
important role in their carcinogenesis. Because of its rar-
ity, there exist diagnostic challenges for pathologists
to differentiate EMP in nasopharynx from chronic in-
flammation or other low-grade B-cell lymphoma with
plasmacytic differentiation. It is important to be able
recognize the combination of two tumors in same site in
order to avoid potential misdiagnosis and improper
management of afflicted patients. A longer period of
follow-up and more case investigation are necessary to
better clarify the biological characteristics and clinical out-
comes of this unusual collision tumor.
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